Medtronic (MDT) Asset Writedowns and Impairment (2014 - 2026)

Medtronic's Asset Writedowns and Impairment history runs 13 years deep, the most recent figure standing at $36.0 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 29.41% year-over-year to $36.0 million; the TTM figure through Jan 2026 stood at $129.0 million (down 68.15% YoY), while the FY2025 annual figure was $123.0 million, down 66.85% from the prior year.
• Asset Writedowns and Impairment came in at $36.0 million for Q1 2026 at Medtronic, down from $38.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $466.0 million in Q2 2022 to a low of -$466.0 million in Q1 2022.
• A 5-year average of $39.4 million and a median of $26.0 million in 2022 frame the typical range for Asset Writedowns and Impairment.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 1764.0% in 2022 and fell as far as 552.43% in 2022.
• Medtronic's Asset Writedowns and Impairment stood at $26.0 million in 2022, then sank by 38.46% to $16.0 million in 2023, then soared by 68.75% to $27.0 million in 2024, then soared by 40.74% to $38.0 million in 2025, then retreated by 5.26% to $36.0 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $36.0 million, $38.0 million, and $28.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison